Trials / Completed
CompletedNCT03341871
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,095 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 0 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
Conditions
Timeline
- Start date
- 2017-12-27
- Primary completion
- 2020-09-15
- Completion
- 2020-09-15
- First posted
- 2017-11-14
- Last updated
- 2021-09-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03341871. Inclusion in this directory is not an endorsement.